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Abstract
 
Indirect evidence suggests that type-I interferons (IFN-
 
 
 
/
 
 
 
) play a significant role in the
pathogenesis of lupus. To directly examine the contribution of these pleiotropic molecules, we
created congenic NZB mice lacking the 
 
 
 
-chain of IFN-
 
 
 
/
 
 
 
R, the common receptor for the
multiple IFN-
 
 
 
/
 
 
 
 species. Compared with littermate controls, homozygous IFN-
 
 
 
/
 
 
 
R-
deleted NZB mice had significantly reduced anti-erythrocyte autoantibodies, erythroblastosis,
hemolytic anemia, anti-DNA autoantibodies, kidney disease, and mortality. These reductions
 
were intermediate in the heterozygous-deleted mice. The disease-ameliorating effects were
accompanied by reductions in splenomegaly and in several immune cell subsets, including B-1
cells, the major producers of anti-erythrocyte autoantibodies. Decreases of B and T cell prolif-
eration in vitro and in vivo, and of dendritic cell maturation and T cell stimulatory activity in
vitro were also detected. Absence of signaling through the IFN-
 
 
 
/
 
 
 
R, however, did not affect
increased basal levels of the IFN-responsive p202 phosphoprotein, encoded by a polymorphic
variant of the 
 
Ifi202
 
 gene associated with the 
 
Nba2
 
 predisposing locus in NZB mice. The data
indicate that type-I IFNs are important mediators in the pathogenesis of murine lupus, and that
reducing their activity in the human counterpart may be beneficial.
Key words: autoimmunity • hemolytic anemia • iﬁ202 • B-1 cells • dendritic cells
 
Introduction
 
Type-I and -II IFNs, initially identified on the basis of their
anti-viral properties, are now known to have multiple effects
on the immune system, affecting differentiation, prolifera-
tion, and survival of B, T, and NK cells, macrophages, and
dendritic cells (DCs),
 
*
 
 and the production of, and signaling
by, other cytokines (for reviews, see references 1 and 2).
These molecules have, therefore, received considerable
attention with regard to their roles in autoimmune diseases,
including systemic lupus erythematosus (SLE).
The participation of IFN-
 
 
 
, the only known type-II
IFN and the main cytokine produced by Th1 cells, in lupus
pathogenesis has been inferred in humans and unequivo-
cally demonstrated in mice (for a review, see reference 3).
The most significant findings are disease inhibition in
(NZBxNZW)F
 
1
 
 and MRL-
 
Fas
 
lpr
 
 mice lacking the IFN-
 
 
 
or IFN-
 
 
 
R genes (4–7), and in MRL-
 
Fas
 
lpr
 
 mice treated with
either soluble recombinant IFN-
 
 
 
R (8) or an IFN-
 
 
 
R/Fc-
encoding plasmid (9).
The role of type-I IFNs (IFN-
 
 
 
/
 
 
 
) in lupus has also
been investigated, but these studies have been limited by
the complexity of this family of molecules (
 
 
 
15 IFN-
 
 
 
, 1
IFN-
 
 
 
) and the lack of broadly reacting Abs. Nonetheless,
increased serum IFN-
 
 
 
 levels in SLE patients correlating
with disease activity has long been known (10), and IFN-
 
 
 
treatment of individuals with viral infections or tumors fre-
quently resulted in SLE-like manifestations (11). The ob-
servation that Ab–DNA complexes stimulate production of
IFN-
 
 
 
 by plasmacytoid DCs, a cell population often found
in SLE skin lesions and lymph nodes, is also potentially rel-
evant (12). More importantly, a recent study (13) provided
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*
 
Abbreviations used in this paper:
 
 AFC, Ab forming cell; BM, bone mar-
row; CFSE, carboxyfluorescein-diacetate-succinimidyl-ester; DC, den-
dritic cell; IRF-1, IFN regulatory transcription factor-1;
 
 
 
PAS, periodic
acid-Schiff;
 
 SLE, 
 
systemic lupus erythematosus.T
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strong evidence that IFN-
 
 
 
 in the serum of lupus patients
is responsible for monocyte differentiation into antigen-
presenting DCs, suggesting a major initiating mechanism of
the autoimmune process. Experiments using mouse models
of lupus that could further support the role of type-I IFNs
in this disease are also limited. Early studies showed that the
IFN-
 
 
 
/
 
 
 
 inducers poly (I:C) accelerated autoimmunity in
(NZBxNZW)F1 mice (14), and renal disease induced in
normal mice by viral infection was inhibited with anti-IFN
Abs (15). Of interest, IFN-
 
 
 
/
 
 
 
 genes are located on chro-
mosome 4 within the boundaries of several NZ lupus sus-
ceptibility loci, including 
 
Sle2
 
, 
 
Nba1/Lbw2
 
, 
 
Spm-1
 
, and
 
Aem-1
 
 (for a review, see reference 16).
In this study, we directly evaluated the role of IFN-
 
 
 
/
 
 
 
in the lupus-like disease of NZB mice by creating congen-
ics lacking IFNAR-1, the 
 
 
 
-chain of the common receptor
for type-I IFNs. Homozygous and even heterozygous IFN-
 
 
 
/
 
 
 
R–deleted mice had significantly reduced serologic,
cellular, and histologic disease characteristics, conclusively
demonstrating that type-I IFN are important mediators in
this disease.
 
Materials and Methods
 
Mice.
 
Female New Zealand Black (NZB) and BALB/c mice
were obtained from the Scripps Research Institute breeding col-
ony (La Jolla, CA). Breeding of NZB mice lacking the 
 
 
 
-chain
of the IFN-
 
 
 
/
 
 
 
R (IFNAR-1, encoded by the 
 
Ifnar1
 
 gene) was
initiated at Genentech, Inc. by backcrossing with the previously
described 
 
Ifnar1
 
-deleted 129Sv mouse (17), and further back-
crossed with NZB mice at Scripps. The 
 
Ifnar1
 
 gene is located on
the distal segment of chromosome 16, where no NZB disease-
predisposing locus has been identified by genome-wide studies
(for a review, see reference 16). Marker assisted selection was
used to obtain mice homozygous for all the NZB predisposing
 
Lbw
 
 loci on chromosomes 1, 4, 5, 7, 17, and 19 by the N4 gen-
eration. The studies presented herein used homozygous IFN-
 
 
 
/
 
 
 
R gene KO, heterozygous (HT), and WT littermate controls
generated by intercrossing mice of at least the N6 generation of
backcrosses.
 
Direct Coomb’s Test.
 
Mice were bled bimonthly from 6 to 12
mo of age. RBCs were diluted 1/1,000 in PBS-1.5%BSA and
100 
 
 
 
l incubated in U-bottom plates with 10 
 
 
 
l of goat anti–
mouse IgG (Southern Biotechnology Associates, Inc.) at a final
concentration of 0, 1, and 10 
 
 
 
g/ml. After 2 h at 37
 
 
 
C, plates
were centrifuged and wells scored for agglutination.
 
Serologic Analysis.
 
Serum levels of IFN-
 
 
 
 before and after in-
traperitoneal injection of 100 
 
 
 
g poly (I:C; Sigma-Aldrich) were
determined using an ELISA kit with a sensitivity of 
 
 
 
5 pg/ml
(PBL Biomedical Laboratories). Serum Igs and autoantibodies
(anti-dsDNA and anti-ssDNA) were assessed by ELISA, as de-
scribed previously (18). Microtiter plates were coated either with
5 
 
 
 
g/ml Fc-specific F(ab
 
 
 
)
 
2
 
 goat anti-mouse IgG (Jackson Immu-
noResearch Laboratories), 5 
 
 
 
g/ml anti–mouse IgM (Southern
Biotechnology Associates, Inc.), 25 
 
 
 
g/ml calf thymus dsDNA,
or 25 
 
 
 
g/ml ssDNA. Total bound IgM or IgG, and IgG sub-
classes were measured by alkaline phosphatase-labeled goat anti–
mouse Abs (Caltag Laboratories) and compared with a standard
serum (Bethyl Laboratories).
 
ELISPOT.
 
The frequency of B cells secreting total IgM, to-
tal IgG, and anti-DNA Abs was determined as described (19).
 
Histology.
 
Autopsies and histologic examinations were per-
formed at 12 mo of age, as detailed previously (20). Tissue sec-
tions were fixed in zinc formalin and stained with periodic acid-
Schiff (PAS) or snap-frozen in OCT for immunofluorescence.
Severity of glomerulonephritis (GN) was determined by analyz-
ing 
 
 
 
50 representative glomeruli graded blindly on a 0 to 4 scale:
0 
 
 
 
 no pathology, 1 
 
 
 
 minimal mesangial thickening, 2 
 
 
 
 no-
ticeable increases in both mesangium and glomerular cellularity,
3 
 
 
 
 the preceding features plus inflammatory exudates and/or
capsular adhesion, and 4 
 
 
 
 obliteration of glomerular architecture
involving 
 
 
 
70% of glomeruli; a score 
 
 
 
 2.0 was considered
pathologic. For immunohistochemistry, kidney sections were air-
dried, fixed in ice-cold acetone, blocked sequentially with 10%
horse or goat serum and an avidin/biotin blocking kit (Vector
Laboratories), and incubated either with anti-IgG-FITC (Vector
Laboratories), anti-CD3-biotin, anti-B220-biotin, anti-I-A
 
d
 
-bio-
tin, anti–ICAM-1 (all from BD Biosciences), anti-F4/80-biotin
(Caltag Laboratories), anti-MCP-1 (Santa Cruz Biotechnology,
Inc.) and, when required, with biotinylated secondary Abs (Jack-
son ImmunoResearch Laboratories). Sections were then incu-
bated with streptavidin horseradish peroxidase (Vector Laborato-
ries), developed with a peroxidase substrate AEC kit (Vector
Laboratories), and counterstained with Mayer’s hematoxylin.
 
Antibodies and FACS
 
®
 
 Analysis.
 
mAbs to B220, Gr-1, CD43
(S7), IgD, CD21/35, CD4, CD8, CD5, CD23, CD44, CD69,
CD25, CD11b, CD11c, CD40, CD80 (B7.1), CD86 (B7.2),
I-A
 
d
 
, H-2K
 
d
 
, erythrocytes and precursors (TER-119), IFN-
 
 
 
,
and annexin-V (AV) were purchased from BD Biosciences. Abs
to IgM and macrophages (F4/80) were from Caltag Laboratories.
Cy5-conjugated streptavidin was from Jackson ImmunoResearch
Laboratories, and biotin-conjugated anti-IgG from ICN Biomed-
icals. For cell surface staining, cells were incubated with various
combinations of mAbs and analyzed on a FACSCalibur™ (Bec-
ton Dickinson). Calibration and color compensation were per-
formed using fluorescent beads and single color controls, per
standard procedures (Becton Dickinson). For intracellular stain-
ing of IFN-
 
 
 
, spleen cells were first stimulated with PMA and
ionomycin and then incubated with Brefeldin A to inhibit intra-
cellular protein transport, as described (9). These cells were then
stained with mAb to CD4 and CD8, fixed in formaldehyde, re-
suspended in Saponin buffer containing 1 
 
 
 
g anti-IFN-
 
 
 
 Ab, and
analyzed by FACS
 
®
 
.
 
In Vivo and In Vitro Proliferations.
 
For in vivo assessments,
mice received autoclaved drinking water containing 0.8 mg/ml
BrdU (Sigma-Aldrich) prepared fresh every 2 d for 9 d, and
spleen cells were stained for various surface-markers and then for
BrdU incorporation (BrdU Flow Kit; BD Biosciences). For in
vitro proliferation, spleen, or peritoneal cells were incubated for
72 h in complete medium containing either 5 
 
 
 
g/ml LPS
(Sigma-Aldrich), 10 
 
 
 
g/ml anti-CD40 plus 1,000 U/ml IL-4
(both from BD Biosciences), 5 
 
 
 
g/ml ConA (Sigma-Aldrich), or
5 
 
 
 
g/ml anti-CD3 (BD Biosciences), and 
 
3
 
H-Thymidine incor-
poration was measured.
 
T Cell Homeostatic Proliferation.
 
Carboxyfluorescein-diace-
tate-succinimidyl-ester (CFSE)-stained whole LN cells (5 
 
 
 
 10
 
6
 
)
from 2–3 mo-old mice were infused into age-matched NZB
mice rendered lymphopenic by sublethal irradiation (600 rads) 1 d
before (21). On days 3, 5, 8, and 14 after transfer, LN cells were
stained with anti-CD4 and anti-CD8 Abs, and CFSE intensity
profiles were defined by FACS
 
®
 
.
B Cell Apoptosis. Spleen cells (106/ml) from 2-mo-old WT
and KO mice were incubated with 10  g/ml of purified F(ab )2
goat anti–mouse IgM (Jackson ImmunoResearch Laboratories)T
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for 18 h, and preapoptotic B220  cells were detected by an-
nexin-V staining (22).
DC Differentiation and Allogenic T Cell Proliferation. A modi-
fied version of the technique described by Gallucci et al. (23)
was used to derive DCs from bone marrow progenitors. Briefly,
RBC-lysed bone marrow cell suspensions were incubated with
biotin-conjugated mAbs to B220, CD4, and CD8 for 30 min at
4 C, washed in PBS-0.1%BSA, and negatively depleted by add-
ing streptavidin-coated beads (Dynal). The purity of non-B,
non-T cells was  98%. For in vitro differentiation of DCs, 5  
106 cells were incubated in 5 ml RPMI-10% FCS medium sup-
plemented with 3 ng/ml GM-CSF and 5 ng/ml IL-4 (both
from BD Biosciences) for 6 d. On days 3 and 6, half of the su-
pernatant was replaced with fresh media containing GM-CSF
and IL-4. To induce final maturation, 1,000 U/ml IFN-  (Cal-
biochem) or 1  g/ml LPS (Sigma-Aldrich) were added for an-
other 24 h. Washed cells were stained with Abs to CD11c,
CD40, CD80, CD86, I-Ad, and H-2Kd, and analyzed by
FACS®. For allogenic mixed lymphocyte reaction, CD3  T
cells were purified from LN and spleen of CBA/J (H-2k) mice
by FACS®. Triplicates of 105 T cells were then incubated with
104 or 3   104 bone marrow (BM) derived, IFN- – or LPS-
induced DCs from WT and KO NZB (H-2d) or normal control
BALB/c (H-2d) mice for 3 d at 37 C, and 3H-Thymidine incor-
poration was measured.
Multiprobe RNase Protection Assay. Riboprobes of defined
length specific for cyclins (D1, D2, D3, E, A, B), cyclin-depen-
dent kinases (CDK4, cdc2), cyclin-dependent kinase inhibitors
(CDKI p16, p18, p19, p21), and a housekeeping gene (L32) were
prepared and labeled with  -(32P)UTP (Riboprobe system;
Promega) as we have described (24). Purified probes were hy-
bridized to 2.5–5  g total cellular RNA (RPA Kit I; Torrey
Pines Biolabs), protected products run on 6% polyacrylamide se-
quencing gels, and intensity of bands measured by overnight ex-
posure in a PhosphorImager (Amersham Biosciences). Results
were expressed as percentage of the housekeeping L32 gene.
IFN-inducible 202 (p202) Protein Levels. Immunoblotting for
the  Ifi202 gene-encoded p202 protein was performed as de-
scribed (25), quantitated by densitometry, and results expressed as
percent of actin protein levels.
Statistics. Unpaired comparisons between groups were ana-
lyzed by the Student’s t test, except for survival rates and serum
(auto)Ab levels, respectively analyzed with the Kaplan-Maier log-
rank test and the Mann-Whitney U test. P   0.05 was consid-
ered significant.
Results
Production of Type-I IFN. To begin evaluating the role
of IFN- /  in systemic autoimmunity, the frequency of
splenic IFN- / –producing DCs and serum levels of
IFN-  were determined in NZB and control BALB/c
mice. The frequency of CD11c CD8 CD4  DCs and
CD11c CD11b B220 Gr-1  DCs, thought to be the
murine counterparts of human IFN- / -producing plas-
macytoid DC (26, 27), was equivalent, and serum IFN- 
was undetectable in both autoimmune and normal mice.
However, while serum IFN-  remained undetectable in
BALB/c mice after poly (I:C) injection, there was variable,
but significant, induction in NZB mice (Fig. 1). This result
suggests that NZB mice may mount faster and/or stronger
responses to microbial and other stimuli, resulting in higher
type-I IFN production.
Immunopathology. To directly explore the role of IFN-
 /  in lupus pathogenesis, we created NZB mice lacking a
functional IFN- / R. Disease characteristics were dramat-
ically reduced in these mice (Figs. 2 and 3). First, KO mice
had significantly greater survival than WT littermate con-
trols (Fig. 2 a), i.e., by 12 mo, 45% of WT mice had suc-
cumbed compared with none of the KO mice (P   0.015),
while the mortality of heterozygous (HT) animals was in-
termediate (11%).
Second, hemolytic anemia, the main pathological mani-
festation of NZB mice, was remarkably reduced in IFN- /
 R KO and, to a lesser degree, in HT mice, as shown by
both incidence and levels of anti-RBC Abs. Thus, 33% of
WT mice were positive by direct Coomb’s test at 6 mo,
78% at 8 mo, and 100% at 10 mo, while no KO mice were
positive at 8 mo, and only 27% at 10 and 12 mo (Fig. 2 b).
Furthermore, the amount of IgG autoantibodies bound on
the surface of RBCs was significantly lower in KO and HT
mice at 10–12 mo (Fig. 2 c). The degree of compensatory
extra medullary erythroblastosis, another indication of the
severity of hemolytic anemia, was also significantly reduced
(Fig. 2 d), i.e., WT mice had marked expansion of splenic
erythroblasts (28%), while KO mice had only 5% (P  
0.02) and HT mice 9% at 12 mo.
Third, kidney disease, although generally not very severe
in NZB mice, was clearly ameliorated in KO mice. Kidney
sections of 12-mo-old KO mice revealed significantly
lower glomerular scores (1.8   0.3 vs. 2.5   0.4, P  
0.05) and IgG deposits (Fig. 3) than age-matched WT lit-
termates. Substantially reduced PAS-staining material in
glomeruli and reduced mesangial proliferation were also
observed. Immunohistochemical analysis indicated absence
of B220  B cells and CD3  T cells in both types of mice.
However, the frequency of infiltrating F4/80  macro-
phages, and expression of MCP-1, class-II MHC, and in-
tercellular adhesion molecule (ICAM)-1 were reduced in
KO mice (data not depicted).
Figure 1. Serum concentrations of IFN-  induced by poly (I:C). WT
NZB (n   3) and control BALB/c (n   4) mice were bled before and, at
different time points, after intraperitoneal injection of poly (I:C) and
IFN-  levels were determined by ELISA.T
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Polyclonal and Anti-DNA Ig Levels and Ab Forming
Cells. At 8 mo, KO and WT mice had similar serum lev-
els of total IgM and IgM anti-ssDNA and anti-dsDNA Ab
(Fig. 4, a and b), although there were fewer spontaneous
IgM-secreting polyclonal and anti-DNA Ab forming cells
(AFCs) in the spleen of KO mice (Fig. 5). The reasons for
the nonconcordance between serum IgM levels and fre-
quency of IgM-secreting cells in the KO mice remain to be
clarified, but such a dissociation has been previously ob-
served by us (unpublished observations) and others (28,
29), and attributed to independent B cell homeostasis and/
or IgM catabolism. Polyclonal IgG subclasses were signifi-
cantly lower in the serum of KO mice (Fig. 4 a), as were
the levels of Abs to ssDNA (several subclasses) and dsDNA
(primarily IgG2a; Fig. 4 b). Marked reductions in the fre-
quency of spontaneous spleen AFC secreting total and anti-
DNA IgG were also detected (Fig. 5).
Spleen, BM, and Peritoneal Cell Populations. IFN- / R
deficiency was associated with a 2–3-fold decrease in the
number of splenic T cells, B cells, and macrophages, con-
sistent with the reduction of average spleen weights in 12
mo-old KO mice to about half that of WT animals (P  
0.002, Table I). The overall proportions of the various cell
subsets were, however, unaffected, with a slight increase in
the frequency of splenic F4/80  macrophages being attrib-
uted to the reduction of erythroblasts. Also, there was no
difference in the frequency of regulatory CD4 CD25 
cells, or activated/memory (CD44hi) splenic CD4  and
CD8  T cells. Significantly, however, the frequency of ac-
tivated splenic B cells (CD19 CD69 ) in KO mice was re-
duced  2-fold compared with WT mice (14.5   1.2% vs.
Figure 2. Mortality rates and hemolytic
anemia. (a) Cumulative survival of IFN- /
 R KO (n   11), HT (n   9), and WT
(n   9) NZB mice followed up to 12 mo;
P   0.015 for KO vs. WT; P   0.05 for HT
vs. WT. (b) Cumulative incidence of direct
Coomb’s test. Mouse groups were the same
as in panel a. HT mice were examined at 12
mo only. (c) FACS® analysis of RBC-
bound IgG autoantibodies in 10–12-mo-old
mice. Each point represents the mean fluo-
rescence intensity unit (FIU) from a single
mouse and horizontal lines indicate the
mean FIU; P   0.004 for KO vs. WT; P  
0.04 for HT vs. WT mice. (d) Frequency of
erythroblasts in spleens of 12-mo-old mice.
RBC-depleted splenocyte suspensions were
stained with an anti-erythroblast Ab
(TER119) and analyzed by FACS®. Results
of a representative mouse from each group
are depicted. Numbers indicate percent of
erythroblasts (mean   SE) of 3–4 mice/
group; P   0.02 for KO or HT vs. WT
mice; P   0.05 for KO vs. HT.
Figure 3. Kidney immunohistology. Representative sections from 12-
mo-old IFN- / R WT and KO NZB mice (n   4 to 10) stained with
PAS or FITC-conjugated anti–mouse IgG are shown.T
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26.2   5.0%, P   0.002), consistent with decreases in both
polyclonal and autoantibody IgG. At 2–3 mo of age, WT
and KO mice were similar in phenotypic characteristics and
percentages of marginal zone (CD23lowCD21high, 23  
1.9%) and follicular (CD23highCD21int, 42   7.8%) B cells,
i.e., KO mice retained the reduced CD23 expression and
the expanded marginal zone B cell population typical of
NZB mice (30). Similarly, BM analysis showed that B cell
development was unaffected in IFN- / R KO mice,
with no difference in the proportions of pro- (B220 
CD43 IgM ), pre- (B220 CD43 IgM ), or immature
(B220 IgM IgD ) B cells compared with WT mice (data
not depicted). In contrast, splenic and, particularly, perito-
neal B-1 cells, considered a major source of autoantibodies
to RBC (31, 32), were significantly reduced in KO mice to
levels similar to nonautoimmune BALB/c mice (Table I
and Fig. 6).
In Vitro and In Vivo Proliferation of Spleen and Peritoneal
Cells. In vitro proliferation of splenic B cells (mostly B-2)
after LPS stimulation, and of peritoneal B cells (mostly B-1)
after stimulation with either LPS or anti-CD40 plus IL-4,
was significantly reduced in KO mice (Table II). Prolifera-
tion of splenic T cells stimulated with ConA or anti-CD3
was, however, equivalent in KO and WT mice. In vivo
turnover (proliferation), assessed at 12 mo of age by long-
term BrdU administration, was significantly reduced in KO
Figure 4. Serum concentrations of (a) polyclonal Ig and (b) anti-ss and dsDNA autoantibodies. BALB/c mice (a pool of 3 individuals) and IFN- / R
WT (n   8), or KO (n   7) NZB mice were analyzed at 10–12 mo. Bars indicate mean   SE; *P   0.05.
Figure 5. Frequency of splenic poly-
clonal Ig and anti-DNA AFCs. ELISPOT
results for total IgM, total IgG, and corre-
sponding anti-dsDNA or anti-ssDNA AFC
in 12-mo-old BALB/c and IFN- / R WT
or KO NZB mice are depicted. Data result
from two separate experiments and each dot
represents a single mouse. In all measure-
ments, P    0.0001 for WT vs. KO or
BALB/c mice.T
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mice for B-1, B-2, and CD8  (but not CD4 ) T cells (Fig.
7 a). Homeostatic T cell proliferation, mediated by recog-
nition of self-MHC/peptide ligands (33) was also assessed
by adoptive transfer of CFSE-stained LN cells from WT or
KO mice into sublethally-irradiated (lymphopenic) WT
NZB hosts. Marked reductions in the percentage of KO
CD8  T cells and, to a lesser extent, CD4  T cells, that
had undergone one or more divisions compared with WT
T cell subsets, were observed (Fig. 7 b).
IFN- –producing T Cells. Signaling via the IFN- / R
is thought to promote induction of IFN-  (1). Therefore,
we investigated whether deletion of this receptor led to
decreases in IFN- -producing T cells. Indeed, KO mice
had a significant reduction in IFN- –expressing CD4 
(10.6   2.8% vs. 20.4   1.7%, P   0.01) and CD8 
(18.1   2.1% vs. 36.0   4.7%, P   0.003) T cells com-
pared with WT mice.
Anti-IgM–mediated Apoptosis. Previous studies indi-
cated that NZB B cells are defective in BCR-mediated
apoptosis (22). Because IFN- /  were shown to inhibit B
cell apoptosis (34–36), we investigated whether this apop-
tosis defect was corrected in the IFN- / R KO mice. Sus-
ceptibility to apoptosis induced by IgM-cross-linking was,
however, equivalent for KO and WT B cells.
DC Maturation and Function. IFN-  in human lupus
sera was recently shown to accelerate differentiation and
maturation of monocytic cells into antigen-presenting
DCs, an effect proposed to play a major role in this disease
(13). We examined the effect of IFN-  on NZB DC mat-
uration and, as expected, WT, but not KO, BM-derived
DCs cultured with recombinant IFN-  up-regulated sig-
nificantly B7.1, B7.2, and class-I MHC, marginally class-II
MHC (Fig. 8a), and not CD40. Consequently, the IFN- 
treated WT DCs induced stronger allogenic T cell re-
sponses than similarly-treated KO DCs (Fig. 8 b). It is no-
table, however, that even without exogenous IFN- , WT
DCs were more efficient in this assay than KO DCs, sug-
gesting that sufficient maturation occurred in response to
endogenous IFN- / , produced at basal levels and/or sec-
ondarily induced during the alloresponse. Interestingly, dif-
ferences between WT and KO DCs were also evident after
in vitro stimulation with LPS, further suggesting the im-
portance of IFN- / R-signaling in DC activity (Fig. 8 b).
IFN- - or LPS-treated BALB/c DC showed equivalent
expression of costimulatory molecules (data not depicted)
and allostimulation (Fig. 8 b) to those of WT NZB mice.
Cell Cycle–related Genes. Previous reports indicated that
IFN- /  can regulate cell-cycle protein expression and
mediate G1 arrest by inducing p21 and p15 genes (for a re-
view, see reference 37). Therefore, the effect of IFN- /
 R deficiency on the expression of several cell cycle-
related genes was assessed by a multiprobe RNase protec-
tion assay. With the exception of a significant reduction of
the CDKI p21 in KO mice (10.4   2.1% vs. 17.4   1.1%,
P   0.02), transcript levels for all other tested genes were
equivalent in WT and KO mice.
Interferon-inducible p202 Expession. An allelic polymor-
phism in the promoter region of the IFN-inducible gene,
Ifi202, which results in high RNA and protein levels of
p202 in B cells (and other non-B, non-T cells), has recently
been implicated as a candidate lupus susceptibility gene for
NZB mice (25). Although spleen cells from WT NZB
Table I. Frequency and Number of Splenic Cell Subsets in BALB/c, IFN- / R WT, and KO NZB Mice
Spleen T cell subsets B cell subsets Macrophages
Mice Weight CD4  CD8  B-2 (CD5 ) B-1 (CD5 ) (F4/80 )
WT 1,006   203 185.9   68.0 64.1   19.2 144.8   48.9 34.7   8.7 62.3   18.4
(25.6   4.3) (9.1   1.4) (20.0   2.3) (5.5   1.6) 8.9   0.9
KO 483   34a 58.1   14.0a 25.8   6.7a 40.7   10.8a 17.1   4.0a 26.9   5.6a
(26.9   1.5) (11.7   0.7) (20.4   4.6) (8.7   2.1) (13.8   1.8a)
BALB/c 288   33 78.2   12.8 26.0   4.8 112.4   18.8 13.3   3.5 14.6   1.3
(32.4   3.3) (10.5   0.8) (46.2   4.2) ( 5.0   0.9) (6.3   0.5)
Mean   SE of spleen wet weight (mg), total number  10 6 and percentage (in parentheses) of splenocyte subset. Data from 11–12-mo-old females
are shown (n   3–6 mice/group). Cells were stained with Abs to CD4, CD8, B220, CD5, and F4/80, then analyzed by flow cytometry (see Materials
and Methods).
aP   0.05 for WT vs. KO.
Figure 6. Frequency of peritoneal B-1 cells. Representative density
plots of total peritoneal lymphocytes are shown, with numbers indicating
percentages (mean    SE) of gated B220 CD5  cells in 12-mo-old
IFN- / R WT and KO NZB mice (n   3–6 mice/group); P   0.01.T
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mice indeed showed higher p202 levels than nonautoim-
mune BALB/c mice, these high levels were retained in
IFN- / R KO NZB mice (Fig. 9), thereby indicating that
signaling through this receptor is not required for high ex-
pression of the Ifi202. Of note, BALB/c mice carry the
same Ifi202 promoter polymorphism as NZB mice (25),
and have been reported to show increased transcription of
this gene after stimulation with IFN-inducers (38). Our re-
sults, however, showed low basal p202 protein expression
in BALB/c mice, thereby supporting a posttranslational
regulation of this gene (39).
Discussion
The present study with NZB mice lacking a functional
IFN- / R directly demonstrates the long-suspected role
of IFN- /  as major effectors in the pathogenesis of sys-
temic autoimmunity. IFN- / R–deficient NZB mice had
significantly reduced serologic and histologic disease char-
acteristics, including anti-erythrocyte autoantibodies and
hemolytic anemia, as well as anti-DNA autoantibodies,
kidney disease, and mortality. Reflecting the pleiotropic
functions of IFN- / , these protective effects were associ-
ated with multiple cellular modifications, including reduced
splenomegaly and numbers of B-1 and B-2 cells, T cells,
macrophages, autoantibody-secreting B cells, and IFN- –
secreting T cells. Proliferative in vitro and in vivo responses
of B and T cells were also decreased, as were the in vitro
maturation and T cell stimulatory capacities of DCs.
The major clinical characteristic of NZB disease is
hemolytic anemia (40). Anti-erythrocyte autoantibody ti-
ters and erythroblastosis were significantly reduced in the
KO mice and, to a lesser degree, in HT mice, suggesting
that even partial ablation of IFN- /  signaling is benefi-
cial. Previous studies have shown that the B-1 subset is the
primary cell type for the production of anti-erythrocyte au-
toantibodies (31, 32). As reaffirmed here, WT NZB mice
have increased B-1 cells in both the peritoneal cavity and
spleen, but these cells were significantly decreased in KO
mice, especially in the peritoneal cavity. Correspondingly,
in vivo proliferation of splenic B-1 cells and in vitro prolif-
eration of peritoneal cells stimulated with either LPS or
anti-CD40 plus IL-4, were reduced. Thus, IFN- /  sig-
naling appears to significantly affect the B-1 subset.
Whether this signaling is acting directly or indirectly
through the induction of other cytokines/chemokines in
Table II. In Vitro Proliferation of Splenocytes and Peritoneal Cells from IFN- / R WT and KO NZB Mice
Splenocytes Peritoneal cells
Mice LPS Con A Anti-CD3 LPS Anti-CD40/IL-4
WT 35.6   1.4 22.9   11.2 122.4   6.7 23.1   2.4 95.8   5.1
KO 23.2   3.7a 21.6   8.8 104.7   17.7 9.8   4.6a 52.1   5.5a
Mean   SE of cpm  10 3 are shown for three 10-wk-old mice/group. 
aP   0.05 for WT vs. KO.
Figure 7. In vivo lymphocyte proliferation. (a) Spontaneous proliferation of splenic B and T cell subsets in 12 mo-old BALB/c, IFN- / R WT, and
KO mice (n   2–3/group) defined by BrdU-incorporation. Representative histograms and percentage of BrdUhi cells (mean   SE) are shown. (b) Lym-
phopenia-induced homeostatic T cell proliferation. LN cells from 2–3 mo-old WT and KO mice were labeled with CFSE and infused into sublethally-
irradiated WT NZB recipients (n   3/group). Representative histograms at 8 d post-transfer and percentage (mean   SE) of cells that had undergone 1
to 7 divisions are shown, with peaks of decreasing CFSE-intensity identifying sequential cellular divisions. Reduced in vivo proliferation of KO T cells
was also observed 5 and 14 d after transfer (data not depicted).T
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the generation, self-renewal, or survival of the B-1 subset,
remains to be determined. Several cytokines and chemo-
kines have been shown to affect B-1 cell numbers, homing
and differentiation, including IFN- , IL-5, IL-10, IL-12, B
lymphocyte chemoattractant (CXCL13), and stromal cell-
derived factor-1 (CXCL12; references 41–45). Some of
these mediators, particularly IL-12 and IFN- , as well as
IL-5 and IL-10, can be induced, and their signaling magni-
fied, by IFN- /  (1, 2, 46, 47).
Conventional B-2 cells and Ig secreting cells were also
decreased in the spleen of KO mice, consistent with reduc-
tions in polyclonal and autoantibody Ig, as well as kidney
immune deposits and pathology. These findings are com-
patible with the reported ability of type-I IFNs to potently
enhance humoral immunity and to promote isotype
switching by DC stimulation in vivo (48). Decreases in B-2
cells could be attributed to defective lymphogenesis, en-
hanced apoptosis, and/or decreased proliferation. Defective
lymphogenesis appears unlikely since KO mice had similar
numbers of B cell precursors as WT mice, and develop-
ment of pro-B cells and their progeny was previously
shown to be reduced at high, rather than low, IFN- / 
levels (49). Increased B cell apoptosis was also considered,
as IFN- /  inhibit this process, presumably by up-regulat-
ing Bcl-2 and Bcl-XL and/or activating NF- B (34–36).
This possibility also appears unlikely, because the resistance
of WT NZB B cells to anti-IgM–induced apoptosis was
not corrected in the KO mice. Therefore, the most likely
possibility is that the decline in B cell numbers is caused by
reduced antigen receptor-mediated proliferative responses,
known to be enhanced by IFN- /  (36).
Significant decreases in splenic T cells, especially in the
CD8  subset, were also observed in KO mice. Although
CD4  T cells are thought to be the primary subset in-
volved in lupus autoimmune responses, studies in  2-
microglobulin-deleted NZB mice suggested that CD8  T
cells may also contribute, particularly with regard to the
anti-erythrocyte response (50). The decline of CD8  cells
in the KO mice may be due to defects in their develop-
ment, decreased proliferation, and/or increased apoptosis.
Impaired development of CD8  cells may result from re-
duced expression of the IFN regulatory transcription fac-
tor-1 (IRF-1), as mice deleted of this gene showed defec-
tive CD8  cell maturation (51, 52). It is of interest that
deletion of IRF-1 confers resistance to CD8  cell-medi-
ated autoimmune diseases (53, 54) while, conversely, dele-
tion of IRF-2, an attenuator of IRF-1 and IFN- /  sig-
naling, leads to development of an inflammatory skin
disease (55). Although type-I IFNs are known to exert
anti-proliferative effects (1), in vivo proliferation of CD8 
T cells in the KO mice was also decreased, as measured by
both BrdU incorporation and lymphopenia-induced ho-
meostatic expansion. It should be noted, however, that the
frequency of proliferating cells defined by these assessments
is a reflection of the balance between dividing and apop-
Figure 8. Maturation and function of DCs. (a) Effect of IFN-  on DC
maturation. BM cells from IFN- / R WT and KO NZB mice were in-
cubated with GM-CSF and IL-4 for 6 d, then with or without IFN-  for
another 24 h to induce final maturation. The frequency of cells that had
up-regulated MHC and B7 costimulatory molecules was determined by
FACS® on gated live, CD11c  cells. Basal levels (horizontal lines) for
MHC class II, B7.1, and B7.2 were set on the basis of parallel stainings in
the absence of the specific antibodies, and for MHC class I on the basis of
constitutive expression defined with specific antibody. Percentages are the
mean   SE of three separate experiments with pooled cells from 3 mo-
old mice (n   2–4/pool); *P   0.05. (b) DCs (3   104) from IFN- / R
WT, KO, and BALB/c mice, derived as described in panel a using either
medium, IFN-  or LPS, were incubated with allogenic T cells (105) for
3 d and proliferative responses determined by H3-thymidine incorpora-
tion. Patterns of allostimulation remained similar when lower numbers
(104) of DCs were used (data not depicted). Results are the mean   SE of
three separate experiments; *P   0.05.
Figure 9. Expression of Ifi202-encoded p202. Protein extracts from
spleens of BALB/c, IFN- / R WT, and KO NZB mice (n   3) were
analyzed by immunoblotting using an anti-p202 polyclonal antiserum.
Representative results are shown. Expression levels (mean   SE) of p202,
calculated as percent of actin expression, were 13.6   3.4% for WT mice,
12.2   1.7% for KO mice, and 0.7   0.2% for BALB/c mice. PC, posi-
tive control (recombinant p202).T
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tosing cells. Recent studies have shown that IFN- /  di-
rectly inhibit apoptosis of activated CD8  (and CD4 ) T
cells without the need of other cytokines nor by raising the
levels of Bcl-2 or Bcl-XL (56). Moreover, it has been re-
ported that survival and proliferation of activated/memory
CD8  cells in vivo is significantly enhanced by type-I IFNs
or their inducers (LPS, CpG DNA, poly I:C), an effect at-
tributed to production of IL-15 by APCs (57, 58). In addi-
tion, efficient activation of naive CD8  T cells was shown
to be dependent on IFN- / –induced CXCR3 chemo-
kine signalling (59). In this context, the decline in p21 in T
cells of the KO mice may also promote apoptosis (24, 37).
Indeed, we have recently shown that p21-deleted lupus-
predisposed BXSB mice have reduced accumulation of
replication- and apoptosis-resistant activated T cells, ac-
companied by disease amelioration (unpublished data).
The absolute number of macrophages was also reduced
in the KO mice, which might lead to less efficient antigen
presentation and, more importantly, decreased participation
of these cells in end-organ inflammatory processes. The
mechanism causing reduced numbers of macrophages in
the KO mice is unclear but, again, a likely possibility is
decreased expression of certain IRFs, such as IRF-1 and
IRF-8, known to exert a major influence on macrophage
maturation and function as well as production of IL-12 and
iNOS (60).
Promoting DC maturation is a major mechanism by
which IFN- /  may contribute to lupus pathogenesis (13).
As expected, incubation of immature, bone marrow–
derived DCs from WT, but not KO, NZB mice with re-
combinant IFN-  significantly enhanced expression of the
costimulatory molecules CD80 and CD86, and of class I
MHC. Correspondingly, WT DCs induced stronger in
vitro T cell alloresponses than KO DCs. It is of interest,
however, that the stimulatory capacity of WT DCs was
equivalent irrespective of whether they had been cultured
with or without exogenous IFN- , presumably because
the levels of endogenous IFN- /  were sufficient to in-
duce appropriate expression of costimulatory and MHC
molecules. Interestingly, even after stimulation with LPS,
the alloresponses induced by WT DCs were more efficient
than those by KO DCs. This finding suggests that induc-
tion of IFN- /  by stimuli of the innate immune system
may promote autoimmune responses through enhanced
self-antigen presentation and engagement of nontolerant,
low affinity, autoreactive T cells.
Several predisposing loci have been identified for NZB
and other lupus strains but, with the exception of a few, the
exact nature of the associated genes is unknown (16, 61,
62). The Nba2/Lbw7 locus on chromosome 1 of NZB
mice, predisposing to autoantibody production, splenome-
galy, and GN, has recently been linked to a polymorphism
in the promoter region of the IFN-inducible Ifi202 gene,
leading to increased p202 expression in B cells and other
non-B, non-T cells (25). The Ifi202 is a family of two
genes, Ifi202a and Ifi202b, and both appear to contribute to
the high p202 levels in NZB mice (unpublished data). The
p202 phosphoprotein is thought to affect cell-signaling
pathways by binding several transcription factors and inhib-
iting cell proliferation and apoptosis (39), but the exact
mechanism by which it predisposes to systemic autoimmu-
nity remains to be elucidated. Although the Ifi202 poly-
morphism is not confined to the NZB strain, backcross
studies have suggested that increased p202 levels contribute
to disease in NZB and (NZBxNZW)F1 mice (25). We
confirmed the high expression of p202 in NZB spleno-
cytes, but found that high expression was maintained in the
absence of IFN- / R, suggesting that signaling through
this receptor is not required for Ifi202 activation. It is con-
ceivable, however, that the two Ifi202 genes may be af-
fected differently by IFN- / R signaling and studies are in
progress to address this question. In addition, previous in-
vestigations have suggested that IFN-  and other factors
can also induce p202 (39). Nonetheless, the findings indi-
cate that the adverse effects mediated by the Nba2-associ-
ated Ifi202 allele (and other predisposing loci) are attenu-
ated in the absence of IFN- / R signaling.
The present results clearly indicate that absence of IFN-
 / R significantly reduces systemic autoimmunity. Al-
though this effect may be a direct consequence of ablating
the IFN- /  activities, it is conceivable that absence of this
receptor may also reduce the adverse effects of IFN-  in
this disease. This possibility stems from the findings that
IFN- /  induce IFN-  production (1), and that a week
IFN- / R stimulation by spontaneously produced IFN-
 /  is necessary for efficient IFN-  signaling (2). The lat-
ter effect appears to be mediated by a physical association
between tyrosine-phosphorylated IFNAR-1 and IFNGR-2
receptor subunits at the caveolar membrane domains,
thereby providing docking sites for efficient STAT-1
dimerization and IFN-stimulated gene factor 3 (ISGF3)
formation (63). The present finding of decreased frequency
of IFN- –producing T cells and of IgG2a autoantibody
levels in the IFN- / R KO mice are compatible with this
concept, and suggests that therapeutic interventions to in-
hibit signaling through the IFN- / R may decrease the
pathogenic effects of both type-I and -II IFNs in lupus.
This and other studies establish that IFNs are key mole-
cules in the pathogenesis of autoimmune diseases, but their
effects may be detrimental or beneficial depending on the
specific clinical entity. Thus, IFN-  promotes lupus (5–9)
and myasthenia gravis (64, 65) but inhibits EAE (66, 67),
whereas IFN- /  promotes lupus (reference 13, and
present study) and IDDM (68) but inhibits myasthenia
gravis (69, 70), EAE, and multiple sclerosis (71). Under-
standing the differences in the autoimmune disease-modi-
fying activities of IFNs and other cytokines will certainly
have a considerable impact in further dissecting the etiolo-
gies and pathways of these syndromes and in developing
new treatments.
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